Multiple Myeloma Information Center
Each year in the United States, close to 20,000 people are diagnosed with multiple myeloma. Thanks to improvements in treatment, however, multiple myeloma patients are living longer. It is estimated that there are more than 56,000 multiple myeloma survivors in the U.S. today.
Advances in targeted therapy, chemotherapy, and stem cell transplantation have contributed to improved multiple myeloma survival. In addition, advances in supportive care have made multiple myeloma treatment more tolerable, leading to improved quality of life.
Understanding multiple myeloma treatment options, the role of different doctors specializing in the treatment of multiple myeloma, and how and when to access new and innovative multiple myeloma treatment options available through clinical trials is essential in order to achieve the best outcome from multiple myeloma treatment.
The Cancer Consultants Multiple Myeloma Information Center has been designed to help patients understand multiple myeloma and multiple myeloma treatment options while providing ongoing information, inspiration, support, and community to individuals affected by a diagnosis of multiple myeloma.
Headline Multiple Myeloma News 
Pesticides Linked to Precancerous Blood Disorder
Individuals who apply pesticides to crops are twice as likely as the general...
Formaldehyde Exposure May Increase Risk of Cancers
Industrial workers who are exposed to formaldehyde may be at an increased...
Thalomid® - Prolongs Survival
One year of treatment with Thalomid® (thalidomide) and prednisone after a...
Multiple Myeloma Tips
Understanding the Goals of Cancer Treatment with Chemotherapy If you’ve been diagnosed with cancer, your healthcare team may have prescribed...
What to Tell Children when Facing a Diagnosis of Cancer If you have children in your life, you already know that they tend to be creatures...
Chemotherapy for Older Patients with Cancer: What You Should Know About the Risk of a Low White Blood Cell Count As you may already know, chemotherapy works by attacking the rapidly dividing cells...
Multiple Myeloma Management
Inspiration, Hope & Resources
On Top of the World: Climbing Everest & Beating Cancer Twice Sean Swarner is a master of setting a goal and achieving it. So when he...
Moving Bodies, Changing Lives Moving On Aerobics helps women regain joy of movement and physical fitness after...
Where Kids Can Be Kids… And Cancer Takes a Back Seat Cancer camps for kids provide fun and camaraderie for children facing down a cancer...
Multiple Myeloma Clinical Trials
06-108 – Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma (MM) Who Are Not Considered Candidates for High-Dose Chemotherapy (HDT) and Autologous Stem Cell Transplantation (SCT): VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP) (C05009)
C05009 – Randomized, Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myelome Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE? (Bortezomib) for Injection, Thalidomide, and Dexamethasone (VTD) versus VELCADE? (Bortezomib) and Dexamethasone (VD) versus VELCADE? (Bortezomib), Melphalan and Prednisone (VMP)
MM03 – PHASE II TRIAL OF ARSENIC TRIOXIDE AND THALIDOMIDE IN THE TREATMENT OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA
 |
 |
 |
 |
